-
Posted by
Two Blokes Apr 30 -
Filed in
Stock
-
0 views
Yu Xuefeng, CEO of Chinese vaccine company CanSino Biologics, says the company remains on-track to breakeven in 2025, and remains committed to expanding into the global market. He also says the impact from US-China trade tensions for the company remains on the margins.
